ASLAN Pharmaceuticals (ASLAN Pharmaceuticals) EV-to-EBIT : -0.58 (As of May. 17, 2024)

View and export this data going back to 2018. Start your Free Trial

What is ASLAN Pharmaceuticals EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, ASLAN Pharmaceuticals's Enterprise Value is $18.11 Mil. ASLAN Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $-30.98 Mil. Therefore, ASLAN Pharmaceuticals's EV-to-EBIT for today is -0.58.

The historical rank and industry rank for ASLAN Pharmaceuticals's EV-to-EBIT or its related term are showing as below:

ASLN' s EV-to-EBIT Range Over the Past 10 Years
Min: -6.27 Med: -1.18 Max: -0.11
Current: -0.58

During the past 10 years, the highest EV-to-EBIT of ASLAN Pharmaceuticals was -0.11. The lowest was -6.27. And the median was -1.18.

ASLN's EV-to-EBIT is ranked worse than
100% of 431 companies
in the Biotechnology industry
Industry Median: 10 vs ASLN: -0.58

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. ASLAN Pharmaceuticals's Enterprise Value for the quarter that ended in Mar. 2024 was $22.19 Mil. ASLAN Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $-30.98 Mil. ASLAN Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -139.63%.

ASLAN Pharmaceuticals EV-to-EBIT Historical Data

The historical data trend for ASLAN Pharmaceuticals's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ASLAN Pharmaceuticals EV-to-EBIT Chart

ASLAN Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-EBIT

Get a 7-Day Free Trial

-1.63

-5.21

-0.64

-0.12

-0.37

ASLAN Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EV-to-EBIT	Get a 7-Day Free Trial															-0.51	-1.37	-0.73	-0.37	-0.72

Competitive Comparison of ASLAN Pharmaceuticals's EV-to-EBIT

For the Biotechnology subindustry, ASLAN Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ASLAN Pharmaceuticals's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ASLAN Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where ASLAN Pharmaceuticals's EV-to-EBIT falls into.

ASLAN Pharmaceuticals EV-to-EBIT Calculation

ASLAN Pharmaceuticals's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	18.114	/	-30.983
	=	-0.58

ASLAN Pharmaceuticals's current Enterprise Value is $18.11 Mil.
ASLAN Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-30.98 Mil.

ASLAN Pharmaceuticals (NAS:ASLN) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

ASLAN Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 )	=	EBIT	/	Enterprise Value (Q: Mar. 2024 )
	=	-30.983	/	22.19000736
	=	-139.63 %

ASLAN Pharmaceuticals's Enterprise Value for the quarter that ended in Mar. 2024 was $22.19 Mil.
ASLAN Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-30.98 Mil.

ASLAN Pharmaceuticals EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of ASLAN Pharmaceuticals's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

ASLAN Pharmaceuticals (ASLAN Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ASLAN Pharmaceuticals Ltd (NAS:ASLN) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

3 Temasek Avenue, Level 18, Centennial Tower, Singapore, SGP, 039190

Website

https://www.aslanpharma.com

ASLAN Pharmaceuticals Ltd is a clinical-stage immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients. The company is evaluating ASLAN004, a potential first-in-class antibody targeting the IL-13 receptor, in atopic dermatitis, and ASLAN003, a potent oral inhibitor of DHODH, which is being developed for autoimmune disease.